These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38835851)

  • 1. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon.
    Lino-Silva LS; Martínez-Villavicencio SB; Rivera-Moncada LF
    World J Clin Oncol; 2024 May; 15(5):587-590. PubMed ID: 38835851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution.
    Yu H; Kong H; Li C; Dong X; Wu Y; Zhuang Y; Han S; Lei T; Yang H
    Transl Cancer Res; 2021 May; 10(5):1975-1983. PubMed ID: 35116520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose methotrexate and zanubrutinib combination therapy for primary central nervous system lymphoma.
    Yadav BS
    World J Clin Oncol; 2024 Mar; 15(3):371-374. PubMed ID: 38576595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful Management of a Patient with Refractory Primary Central Nervous System Lymphoma by Zanubrutinib.
    Cheng Q; Wang J; Lv C; Xu J
    Onco Targets Ther; 2021; 14():3367-3372. PubMed ID: 34079282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zanubrutinib in the Maintenance Treatment of Elderly People with Primary Central Nervous System Lymphoma: A Report of 2 Cases.
    Liu Y; Sun J; Tuo K
    Case Rep Oncol; 2023; 16(1):227-233. PubMed ID: 37069896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy.
    Wang N; Chen FL; Pan L; Teng Y; Wei XJ; Guo HG; Jiang XM; Huang L; Liu SC; Liang ZL; Li WY
    World J Clin Oncol; 2023 Dec; 14(12):606-619. PubMed ID: 38179402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Bruton's tyrosine kinase in primary central nervous system lymphoma.
    Steffanoni S; Batchelor TT
    Curr Opin Neurol; 2021 Dec; 34(6):848-856. PubMed ID: 34581302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bruton's tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review.
    Shen J; Liu J
    Front Oncol; 2022; 12():1034668. PubMed ID: 36465385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives].
    Nagane M
    Rinsho Ketsueki; 2022; 63(9):1145-1156. PubMed ID: 36198540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series.
    Yang C; Cui Y; Ren X; Li M; Yu K; Shen S; Jiang H; Li M; Zhang X; Zhao X; Zhu Q; Lin S
    Front Oncol; 2022; 12():901797. PubMed ID: 35785180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse.
    Du P; Chen H; Shen L; Liu X; Wu X; Chen L; Cao A; Geng D
    Curr Oncol; 2022 Sep; 29(9):6642-6656. PubMed ID: 36135091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
    Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful Consolidation/Maintenance Therapy with Single Agent Ibrutinib for Primary CNS Lymphoma after Initial Induction Therapy.
    Du S; Bota D; Kong XT
    Neurol Int; 2022 Jun; 14(3):574-580. PubMed ID: 35893281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary central nervous system lymphoma: clinicopathological and genomic insights for therapeutic development.
    Tateishi K; Miyake Y; Nakamura T; Yamamoto T
    Brain Tumor Pathol; 2021 Jul; 38(3):173-182. PubMed ID: 34255226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical characteristics and prognosis of 49 newly diagnosed primary central nervous system diffuse large B-cell lymphoma].
    Song J; Liu H; Shen HL; Yue LZ; Yang XJ; Song WJ; Sun CY; Yu SZ; Ding K; Wang YH; Li LJ; Yu H; Shao YY; Wang CM; Yue SY; Fu R
    Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):917-922. PubMed ID: 35045653
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
    Narita Y; Nagane M; Mishima K; Terui Y; Arakawa Y; Yonezawa H; Asai K; Fukuhara N; Sugiyama K; Shinojima N; Kitagawa J; Aoi A; Nishikawa R
    Neuro Oncol; 2021 Jan; 23(1):122-133. PubMed ID: 32583848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience With Tirabrutinib in the Treatment of Primary Central Nervous System Lymphoma that Is Difficult to Treat With Standard Treatment.
    Yoshioka H; Okuda T; Nakao T; Fujita M; Takahashi JC
    Anticancer Res; 2022 Aug; 42(8):4173-4178. PubMed ID: 35896257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors.
    DeAtkine AB; Abdelrashid M; Tucker Z; Mehta A; Markert JM; Kim J; Fiveash JB; Oster RA; Lobbous M; Nabors LB
    J Neurooncol; 2022 May; 158(1):33-40. PubMed ID: 35441948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updates of primary central nervous system lymphoma.
    Wu J; Zhou D; Zhu X; Zhang Y; Xiao Y
    Ther Adv Hematol; 2024; 15():20406207241259010. PubMed ID: 38883164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel insights into the biomarkers and therapies for primary central nervous system lymphoma.
    Zhai Y; Zhou X; Wang X
    Ther Adv Med Oncol; 2022; 14():17588359221093745. PubMed ID: 35558005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.